|
|
|
| home > ebr > Summer 2016 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
Editor’s Letter
EBR’s Editor Deborah O’Neil introduces July’s edition by highlighting the speed at which pharma is moving towards an age of biologics, while discussing the emerging possibility of earlier diagnosis for all patients.
|
|
|
|
Dementia Spotlight
How to Get a Pre-Competitive Edge
Rodrigo Barnes at Aridhia discusses the possibility of unlocking the secrets of dementia to reduce its effect. With the costs of the disease – both economic and personal – on the rise, the time is right for a more collaborative approach to curing it.
|
|
|
Liquid Biopsies
Translating Research into Reality: Part 1
As DNA sequencing looks increasingly towards the use of liquid biopsies, the industry moves ever-closer to developing personalised treatment for all patients. Paul Elvin at Aptus Clinical explains the need to target specific mutations, and the effect that new ctDNA analysis may have on patients and developers alike.
|
|
|
|
|
Biomarkers and Diagnostics
The Secrets in our Cells
Diamond Light Source’s Mary Cruse sheds light upon recent work undertaken in cancer research, and the prospect of tailoring treatment to the genetic codes of any given patient – stating that perhaps the successful cure lies in each individual’s chemistry.
|
|
|
|
Comment: Shipment Conditions
How Strong is a Peptide Bond?
Have you ever wondered how much you could save on your logistics costs? According to Dr Henk J Bak at Eurosequence, there is a simple solution: bidding farewell to outdated methods and adopting more relevant shipping procedures.
|
|
|
In Brief
Less is More
Governments, payers and patients alike are all calling for businesses worldwide to “do more with less”. Emile Bellott looks at the challenges we face as demands placed on the healthcare system threaten to intensify.
|
|
|
|
Content Management Software
Curse of the Patchwork Monster
The transformation of the life sciences landscape due to the digital revolution has created a stronger, quicker supply chain process. However, John Chinnici at Veeva Systems explains that despite its benefits, paper-based processes are still used by many companies. This can be combatted by implementing a fully digitalised supply chain.
|
|
|
|
eHealth Revolution
From the Outside
Innovation from external sources has the potential to revolutionise the
biopharma industry. Dr Ulrica Sehlstedt, Nils Bohlin, Fredrik de Maré andDr Richard Beetz at Arthur D. Little suggest that by embracing
the digital, a positive change could be created for patient care, even if it
means advances in other areas lose pace. |
|
|
|
Q&A: Idiopathic Pulmonary Fibrosis
Breathing Easy
In our latest Q&A, Dr Marilyn Glassberg enlightens EBR on everything from the main themes raised at ATS 2016 to her recent research, before revealing her biggest lesson in life.
|
|
|
|
Two-Photon Microscopy
The Next Step
A plethora of options have emerged to improve imaging capabilities for microscopists. Laser Quantum’s Andrew Wells explains the change in the priorities of manufacturers of laser equipment, and discusses the benefits of using ultra-fast lasers.
|
|
|
|
Cell Disruption
Under Pressure
Technology that performs mechanical lysis and homogenisation of cells are often sold on the basis of the pressure they are able to reach. Recent research undertaken by Dr Matthew Lougher of Constant Systems, however, demonstrates that the success of mechanical cell disruptions depends on much more than pressure.
|
|
|
Cell Culture Development
Up to Speed
Research shows that reducing the development time and costs associated with cell culture processes can be achieved by instigating high-throughput methods. Shahid Rameez and Abhinav A Shukla at KBI Biopharma discuss what this means for progress in novel biotherapeutics and their use in clinical trials.
|
|
|
|
Biosimilar Manufacturing
Gaining Ground
ProductLife Group’s Barbara Testa highlights the fact that the biosimilar sector is wrought with challenges regarding patient satisfaction and understanding – she explains that biosimilar popularity continues to rise, but physicians remain tentative. |
|
|
Genetic Disorder Therapeutics
Two Pillars of Fledgling RNA Medicine
It is becoming progressively difficult to find efficient, predictable and safe intracellular delivery strategies for curing genetic disorders. With the hope that a fuller understanding of RNA therapies will accelerate the process, Max Ryadnov at the National Physical Laboratory outlines the two main obstacles facing researchers and developers.
|
|
|
Developments in Biosimilars
Winning the Race
The biosimilar testing process is complex, but it is becoming increasingly possible to employ a successful development programme. Dr Jon S Kauffman, Dr Weihong Wang and Dr Frederic Girard at Eurofins explore the feasibility of implementing these methods across the biopharma sector.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
ChemAxon and AWS simplify getting scientists moving on the cloud
Listen to a talk
by Paul Underwood of AWS introducing Biotech Blueprint, a cloud based
solution for cheminformatics. The technology for novel compound registration is
provided by ChemAxon.
More info >> |
|
 |
White Papers |
 |
|
Tabletability, Compactability, and Compressibilty: What’s the Difference?
Natoli Engineering Company, Inc.
To patients and consumers, tablets are a simple and convenient dosage form. But the science behind compressing a block of particles or granules into a single tablet can be complicated. That’s where common compression studies can help. This article explains how to develop tabletability, compactibility, and compressibility profiles.
More info >> |
|
 |
Industry Events |
 |
SMi’s 9th Annual Biosimilars & Biobetters Conference
25-27 September 2018, Copthorne Tara Hotel, London, UK
Following the success of our previous events in both London and the US,
Biosimilars and Biobetters UK 2018, SMi deliver a stellar speaker
line-up and bring together a global audience of biosimilar experts to
discuss the latest developments and future of the rapidly evolving and
expanding biosimilars market.
More info >> |
|
|
